Sara Gutiérrez Pelaz

Dr. Sara Gutiérrez Pelaz

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 October 2022 in Oncogene
Verified
Journal Article
Open access
PDF file
SPSara Gutiérrez Pelaz
Sara Gutiérrez Pelaz
ATArantxa Tabernero
Arantxa Tabernero
Metabolism must be tightly regulated to fulfil the dynamic requirements of cancer cells during proliferation, migration, stemness and differentiation. Src is a node of several signals involved in many of these biological processes, and it is also an important regulator of cell metabolism. Glucose uptake, glycolysis, the pentose-phosphate pathway and oxidative phosphorylation are among the metabolic pathways that can be regulated by Src. Therefore, this oncoprotein is in an excellent position to coordinate and finely tune cell metabolism to fuel the different cancer cell activities. Here, we provide an up-to-date summary of recent progress made in determining the role of Src in glucose metabolism as well as the link of this role with cancer cell metabolic plasticity and tumour progression. We also discuss the opportunities and challenges facing this field.

1 December 2020 in EBioMedicine
Verified
Journal Article
Open access
SPSara Gutiérrez Pelaz
Sara Gutiérrez Pelaz
MJMyriam Jaraíz-Rodríguez
Myriam Jaraíz-Rodríguez
AÁAndrea Álvarez-Vázquez
Andrea Álvarez-Vázquez
RTRocío Talaverón
Rocío Talaverón
LGLaura García-Vicente
Laura García-Vicente
ATArantxa Tabernero
Arantxa Tabernero
Glioblastoma is the most aggressive primary brain tumour and has a very poor prognosis. Inhibition of c-Src activity in glioblastoma stem cells (GSCs, responsible for glioblastoma lethality) and primary glioblastoma cells by the peptide TAT-Cx43266-283 reduces tumorigenicity, and boosts survival in preclinical models. Because c-Src can modulate cell metabolism and several reports revealed poor clinical efficacy of various antitumoral drugs due to metabolic rewiring in cancer cells, here we explored the inhibition of advantageous GSC metabolic plasticity by the c-Src inhibitor TAT-Cx43266-283. Metabolic impairment induced by the c-Src inhibitor TAT-Cx43266-283 in vitro was assessed by fluorometry, western blotting, immunofluorescence, qPCR, enzyme activity assays, electron microscopy, Seahorse analysis, time-lapse imaging, siRNA, and MTT assays. Protein expression in tumours from a xenograft orthotopic glioblastoma mouse model was evaluated by immunofluorescence. TAT-Cx43266-283 decreased glucose uptake in human GSCs and reduced oxidative phosphorylation without a compensatory increase in glycolysis, with no effect on brain cell metabolism, including rat neurons, human and rat astrocytes, and human neural stem cells. TAT-Cx43266-283 impaired metabolic plasticity, reducing GSC growth and survival under different nutrient environments. Finally, GSCs intracranially implanted with TAT-Cx43266-283 showed decreased levels of important metabolic targets for cancer therapy, such as hexokinase-2 and GLUT-3. The reduced ability of TAT-Cx43266-283-treated GSCs to survive in metabolically challenging settings, such as those with restricted nutrient availability or the ever-changing in vivo environment, allows us to conclude that the advantageous metabolic plasticity of GSCs can be therapeutically exploited through the specific and cell-selective inhibition of c-Src by TAT-Cx43266-283. Spanish Ministerio de Economía y Competitividad (FEDER BFU2015-70040-R and FEDER RTI2018-099873-B-I00), Fundación Ramón Areces. Fellowships from the Junta de Castilla y León, European Social Fund, Ministerio de Ciencia and Asociación Española Contra el Cáncer (AECC).

24 August 2021 in Cancers
Verified
Journal Article
Open access
PDF file
SPSara Gutiérrez Pelaz
Sara Gutiérrez Pelaz
COClaudia Ollauri-Ibáñez
Claudia Ollauri-Ibáñez
Conchi LilloConchi Lillo
Conchi Lillo
ATArantxa Tabernero
Arantxa Tabernero
Autophagy is a physiological process by which various damaged or non-essential cytosolic components are recycled, contributing to cell survival under stress conditions. In cancer, autophagy can have antitumor or protumor effects depending on the developmental stage. Here, we use Western blotting, immunochemistry, and transmission electron microscopy to demonstrate that the antitumor peptide TAT-Cx43266-283, a c-Src inhibitor, blocks autophagic flux in glioblastoma stem cells (GSCs) under basal and nutrient-deprived conditions. Upon nutrient deprivation, GSCs acquired a dormant-like phenotype that was disrupted by inhibition of autophagy with TAT-Cx43266-283 or chloroquine (a classic autophagy inhibitor), leading to GSC death. Remarkably, dasatinib, a clinically available c-Src inhibitor, could not replicate TAT-Cx43266-283 effect on dormant GSCs, revealing for the first time the possible involvement of pathways other than c-Src in TAT-Cx43266-283 effect. TAT-Cx43266-283 exerts an antitumor effect both in nutrient-complete and nutrient-deprived environments, which constitutes an advantage over chloroquine and dasatinib, whose effects depend on nutrient environment. Finally, our analysis of the levels of autophagy-related proteins in healthy and glioma donors suggests that autophagy is upregulated in glioblastoma, further supporting the interest in inhibiting this process in the most aggressive brain tumor and the potential use of TAT-Cx43266-283 as a therapy for this type of cancer.

5 August 2026 in Nature
Verified
Journal Article
Open access
PDF file
SPSara Gutiérrez Pelaz
Sara Gutiérrez Pelaz
KMKatsukuni Mitsui
Katsukuni Mitsui
NKNatalia Kolosowska
Natalia Kolosowska
HFHaley Fritch
Haley Fritch
CNChiranjivi Neupane
Chiranjivi Neupane
BKBaljit S. Khakh
Baljit S. Khakh
Understanding how adverse life events trigger stress-related behavioural changes remains an unresolved challenge. The amygdala is integral to emotion and stress responses 1 and comprises astrocytes, neurons and other cells. Here we show that amygdala astrocytes contribute to stress-related behaviours through signalling mechanisms related to their primary cilia 2 . Amygdala astrocytes are altered during stress at the protein and gene expression level, display reduced expression of molecules related to primary cilia 3,4 and have morphologically short primary cilia 5,6 . G protein-coupled receptors (GPCRs) are central to astrocyte 7 and primary cilia 2,8,9 function. Therefore, we speculated that GPCR signalling activation might be beneficial in stress-related behavioural disorders. We identified amygdala astrocyte GPCRs as regulators of responses following stress. Chemogenetics and targeting of native sphingosine-1-phosphate receptor 1 (S1PR1) GPCRs led to the restoration of astrocyte primary cilia length, corrected molecular alterations and improved stress-related behaviours. Cilium-related genes were abundantly expressed in human amygdala astrocytes, with many displaying disrupted expression in stress-related brain disorders. S1PR1 was also highly expressed in amygdala astrocytes from human tissue. Selective genetic disruption of amygdala astrocyte primary cilia in mice altered some stress-related behaviours and gene expression of astrocytes and parenchymal cells. These data confirm that astrocytic cilia have important roles in this brain nucleus. In summary, amygdala astrocytes and their primary cilia are disrupted during stress, and their restoration is accompanied by stress-related molecular and behavioural improvements. Astrocyte primary cilia-related mechanisms may therefore provide new treatment strategies for stress-related and other brain disorders.

28 November 2019 in bioRxiv
Verified
Preprint
Open access
PDF file
SPSara Gutiérrez Pelaz
Sara Gutiérrez Pelaz
MJMyriam Jaraíz-Rodríguez
Myriam Jaraíz-Rodríguez
RTRocío Talaverón
Rocío Talaverón
LGLaura García-Vicente
Laura García-Vicente
MCMarta Gómez de Cedrón
Marta Gómez de Cedrón
ATArantxa Tabernero
Arantxa Tabernero
Glioblastoma is the most aggressive primary brain cancer, with a median survival of 1 to 2 years 1 . These tumours contain glioma stem cells (GSCs), which are highly tumorigenic, resistant to conventional therapies 2, 3 , and exhibit metabolic plasticity to adapt to challenging environments 4, 5 . GSCs can be specifically targeted by a short cell-penetrating peptide based on connexin43 (Cx43) (TAT-Cx43 266-283 ) that reduces tumour growth and increases survival in preclinical models 6 via c-Src inhibition 7 . Because several reports revealed poor clinical efficacy of various antitumoral drugs due to metabolic rewiring in cancer cells 8–10 , we investigated the effect of TAT-Cx43 266-283 on GSC metabolism and metabolic plasticity. Here we show that TAT-Cx43 266-283 decreases GSC glucose uptake and oxidative phosphorylation without a compensatory increase in glycolysis, with no effect on neuron or astrocyte metabolism. GSC changes were mediated by decreased hexokinase (HK) activity and aberrant mitochondrial localization, ultrastructure and function. Moreover, TAT-Cx43 266-283 reduced GSC growth and survival under different nutrient availability conditions by impairing the metabolic plasticity needed to exploit glucose as an energy source in the absence of other nutrients. Finally, GSCs intracranially implanted into mice together with TAT-Cx43 266-283 showed decreased levels of important targets for cancer therapy, such as HK-2 11, 12 and glucose transporter 3 (GLUT-3) 13 , evidencing the reduced ability of treated GSCs to survive in challenging environments. Our results confirm the value of TAT-Cx43 266-283 for glioma therapy alone or in combination with therapies whose resistance relies on metabolic adaptation. More importantly, these results allow us to conclude that the advantageous metabolic plasticity of GSCs is a targetable vulnerability in malignant gliomas.